congenital cmv infection
DESCRIPTION
TRANSCRIPT
![Page 1: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/1.jpg)
Congenital CMV infection
Siriporn phongjitsiri,MDPediatric Infectious Division
Queen Sirikit National Institute of Child HealthJuly 27,2007
![Page 2: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/2.jpg)
Congenital CMV infection Congenital CMV infection
• Approximately 0.15–2% of live births
• Leading cause of sensorineural deafness
• Major cause of mental retardation, cerebral palsy
• Approximately 10% death in symptomatic newborns
• Lifelong habilitation for impaired survivors
![Page 3: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/3.jpg)
• Fetus: Via placenta from the mother• Human milk• Blood transfusion, organ transplantation• Children and adults: Mainly via bodily
fluids (esp. urine, saliva)
How is CMV transmitted?
![Page 4: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/4.jpg)
• Duration of viral shedding following primary infection:
• 2-3 weeks for adults
• Months to years for young children
• Therefore, CMV is most often transmitted by young children
Who transmits CMV?
![Page 5: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/5.jpg)
Transmission of CMV through the placenta barrier and infection of the fetusTransmission of CMV through the placenta barrier and infection of the fetus
Infected mother viraemia infection of placenta trophoblasts
Infection of fetalendothelial cells
Viralreplication intarget organs
(kidney)
Fetal viruria
Virus inamniotic fluid
Infection ofthe oropharynx
Fetal viraemia
![Page 6: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/6.jpg)
PRIMARY MATERNAL CMV INFECTION DURING PREGNANCY
• 95% clinically inapparent
• 35% transmitted to fetus
• No clear relationship between gestational age and transmission
• Fetal damage more likely in first 26 weeks, (32%) than later (15%)
![Page 7: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/7.jpg)
MATERNAL CMV INFECTION DURING PREGNANCY • Primary maternal infection leads to fetal
infection in 30-50% of cases--10-15% of these have overt clinical disease
• Secondary maternal infection less likely to lead to fetal infection (1-2% ) but can do so and may lead to severe disease (Boppana et al, NEJM 2001, 344: 1366)
![Page 8: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/8.jpg)
Rates of primary CMV infection during pregnancyRates of primary CMV infection during pregnancy
Study (Location) Rate as % of Rate as % of % cong CMV,Pregnancies Seronegatives primary mat
inf
Stern 1.1 4.1 45(London)
Grant (Scotland) 0.29 0.71 38
Stagno (USA, 0.57 1.4 47mid-income)
Ahlfors (Sweden) 0.32 1.4 43
Griffiths (London) 0.30 0.86 20
![Page 9: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/9.jpg)
![Page 10: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/10.jpg)
Symptomatic Congenital CMV Infection
• Jaundice (67%)• Petechiae (76%)• Hepatosplenomegaly (60%)• Microcephaly (53%)• Chorioretinitis (20%)• Seizure (7%)• Fatal outcome (10%)
Boppana et al . (1999 ) Pediatrics 104:55
![Page 11: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/11.jpg)
Sequelae of Congenital CMV Infections
• Neurological sequelae are the most common, and most severe: • >90% of newborns with symptomatic
congenital CMV infection have visual, audiologic and/or other neurological sequelae
• - 5-17% of newborns with asymptomatic congenital CMV infection develop neurological sequelae (esp. hearing loss)
![Page 12: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/12.jpg)
Sequelae of Congenital CMV Infections
• Cranial CT is a good predictor of sequelae in neonates with congenital CMV infection
• Most common abnormality is intracerebral calcification (typically periventricular)
• Boppana et al (Pediatrics 99:409, 1997) reported that 90% of neonates with abnormal CT scan developed at least 1 sequelae
• Only 1/17 neonates with normal CT had IQ < 70
![Page 13: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/13.jpg)
SEQUELAE OF SYMPTOMATIC CONGENITAL CMV INFECTION
• Seizures• Chorioretinitis• Periventricular calcifications• Sensorineural hearing loss• motor deficits
![Page 14: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/14.jpg)
CHORIORETINITIS
![Page 15: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/15.jpg)
Congenital CMV
![Page 16: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/16.jpg)
Congenital CMV
![Page 17: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/17.jpg)
![Page 18: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/18.jpg)
CHARACTERISTICS ASSOCIATED WITH INCREASED RISK OF SEQUELAE
• Primary maternal infection• Symptomatic congenital CMV
infection• Presence of neonatal neurological
abnormalities• Abnormal head CT scan• Chorioretinitis in the newborn
![Page 19: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/19.jpg)
CLINICAL IMPACT OF CONGENITAL CMV INFECTION
Frequency of sequelae Symptomatic (7%)
Asymptomatic (93%)
Infant death 10% 0
Hearing loss 60% 7–15%
Mental retardation 45% 2–10%
Cerebral palsy 35% <1%
Chorioretinitis 15% 1–2%
![Page 20: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/20.jpg)
Diagnosis of Congenital CMV Infections
• Isolation of CMV from urine or other body fluid (CSF, blood, saliva) in the first 21 days of life is considered proof of congenital infection
• Serologic tests are unreliable; IgM tests currently available have both false positive and false negative results
• PCR may be useful in selected cases
![Page 21: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/21.jpg)
![Page 22: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/22.jpg)
Detection: screening for maternalCMV infectionDetection: screening for maternalCMV infection
• CMV IgG antibody – sensitive and specific screen for past infection
• CMV IgM antibody – variable sensitivity and specificity
• Antibody avidity testing can increase accuracy of detection of primary infection
• No test for immune mothers who will transmit
![Page 23: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/23.jpg)
![Page 24: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/24.jpg)
Advanced CMV diagnosisAdvanced CMV diagnosis
IgM confirmation by Western blot
Determination of the IgG avidity index
Isolation of the virus from urine, saliva and blood
![Page 25: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/25.jpg)
A confirmatory test for CMV-IgMA confirmatory test for CMV-IgM
New immunoblot
1) Contains both structural and nonstructural proteins
2) Reactivity to vp 150 can be confirmed with recpUL32
3) Agrees with consensus of different ELISAs
4) Is easy to standardize
5) Is easy to interpret
rp150
rp52
rp130
CKS
rp38
Purifiednativeviral
proteins
Recombinantproteins
Vp28
Vp65Vp82
Vp150
![Page 26: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/26.jpg)
Weeks after beginning of symptoms
Avi
dity
inde
x (%
)
70
0
60
50
40
30
20
10
05 10 15 20 25 30 35
Congenital CMV infectionsCongenital CMV infections
Low IgG avidity is linked to primary infection
![Page 27: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/27.jpg)
Evaluation of mothers at risk of transmitting CMV to the fetusEvaluation of mothers at risk of transmitting CMV to the fetus
N eg ative ,n o fu rth er tes tin g
P os it ive =p rim ary in fec tion
Tes t fo r Ig M A n tib od y
P os it ive
Ig G P os it ive =S erocon vers ion
N eg ative ,n o fu rth er tes ts
R etes t la te r
N eg ative
Tes t fo r Ig G an tib od ya t firs t p ren a ta l vis it
Refer for prenatal diagnosis
![Page 28: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/28.jpg)
Intervention: using results of maternal screening to prevent congenital CMV disease
Intervention: using results of maternal screening to prevent congenital CMV disease
Possible intervention
• Counsel regarding prevention (seroneg mother)
• Use prenatal diagnosis, abort infected fetus
• Use antivirals to prevent or treat fetal infection
Problems
• No proven means to prevent maternal infection
• ~75% infected fetuses will be normal
• No available antiviral treatment for prenatal use
![Page 29: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/29.jpg)
Case Report: “Oral ganciclovirfor the treatment of intrauterine cytomegalovirus infection
• Nulligravid cmv seronegative pt. received renal allograft from seropositive donor
• Pt. became pregnant 3 months following acute CMV infection
• AF CMV DNA+(80 copies) at 21 wks.
• Oral CGV administered at 22 wks.• AF CMV DNA-at 26 weeks (8 copies)• Vigorous female delivered at birth• Newborn urine and blood CMV DNA-• Normal development @ 3 years of age
Puliyandaet al . (2005)Transplant Infectious Disease 7:71-7
![Page 30: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/30.jpg)
Antiviral Therapy for Congenital CMV Infection?
![Page 31: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/31.jpg)
• 100 Neonates enrolled to receive 6 weeks of IV ganciclovir (6 mg/kg/dose q 12 hours)
• No significant difference in mortality (6% GCV, 12% untreated)
• Hearing Improvement was more likely in the GCV treated group at 6 and 12 mos (OR 4.31, 4.03)
• 29/46 (63%) GCV recipients experienced neutropenia, compared with 9/43 (21%) untreated control patients
Kimberlin et al, J. Pediatrics,143:17,2003
Phase lll randomized trial of ganciclovir for symptomatic congenital CMV infections involving the CNS
![Page 32: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/32.jpg)
USE OF GANCICLOVIR IN SYMPTOMATIC CONGENITAL CMV INFECTION
• 12 newborns treated for 2 weeks with 5 mg/kg/day or 7.5 mg/kg/day + 3 months of 10 mg/day 3x/week
• Higher, but not lower dose, cleared viruria• Abnormal liver and haematologic function
appeared to clear faster with higher dose• Although outcome appeared better with higher
dose, CNS sequelae appeared in both groups
from Nigro et al, J Pediatr 1994; 124: 318
![Page 33: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/33.jpg)
A PHASE II STUDY OF GANCICLOVIR IN 47 NEWBORNS WITH SYMPTOMATIC CONGENITAL CMV INFECTION
• Patients with CNS disease treated with 8mg/kg/d or 12mg/kg/d iv for 6 weeks
• 19 % of participants had neutropenia requiring dose modification
• 12 mg/kg reduced viral shedding; shedding returned when drug was discontinued
• 3 patients had improved hearing at 6 months; 25 had abnormal hearing
from Whitley et al, J Infect Dis, 1997; 175: 1080
![Page 34: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/34.jpg)
Antiviral Therapy for Congenital CMV Infection?
• Ganciclovir has been shown to be effective therapy for certain CMV infections in immunocompromised hosts (e.g., retinitis or enterocolitis in HIV-infected patients)
• Neonatal experience with ganciclovir is limited, the toxicity of the drug is considerable (e.g., platelets, neutrophils), and oral bioavailability unreliable
![Page 35: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/35.jpg)
Ganciclovir Therapy for Congenital CMV? 2006
• A six week course of IV ganciclovir may reduce the rate of long-term hearing loss in neonates with symptomatic CMV infection
• However, this regimen is associated with significant toxicity, long-term followup data are lacking, and the optimal duration of therapy (if any) is unknown
• Potential benefits of antiviral therapy for asymptomatically infected neonates may be greater
![Page 36: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/36.jpg)
Antiviral Therapy for Congenital CMV? 2006
• Current role for IV ganciclovir uncertain: therapy “may be considered for patients with symptomatic congenital CMV disease involving the CNS” (Kimberlin et al, 2003)
• 2006 Red Book says that it “is not recommended routinely because of insufficient efficacy data”
• ?? Treatment of neonates with worsening retinitis or hepatitis, severe pneumonia, or persistent severe thrombocytopenia ?? Duration of therapy ??
![Page 37: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/37.jpg)
Prevention of CMV Infections?
• A vaccine to prevent CMV infections is desperately needed
• Trials of candidate vaccines are underway
• CMV Vaccine development a “Level One” priority !!
![Page 38: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/38.jpg)
How is congenital CMV prevented?
• Many different ways toprevent CMV
• Our approach:
• Hygiene, especially handwashing
• Education about CMV and how to prevent it through hygiene
![Page 39: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/39.jpg)
How do we communicate this message?
![Page 40: Congenital cmv infection](https://reader036.vdocuments.site/reader036/viewer/2022081413/54991ca6b47959422b8b4936/html5/thumbnails/40.jpg)
The End